What You Should Know for the 2016-2017 Influenza Season
Upcoming Flu SeasonNote: On June 22, 2016, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended a change to U.S. influenza vaccination policy for 2016-2017. The ACIP recommendation must be reviewed and approved by CDC’s Director, and the final recommendations will be published in a CDC Morbidity and Mortality Weekly Report (MMWR), in late summer or early fall. The content of this website will be reviewed and updated prior to the 2016-2017 influenza season.
On March 4, 2016, the Food and Drug Administration's Vaccines and Related Biologics Advisory Committee (VRBPAC) endorsed the WHO-recommended vaccine viruses for use in all U.S. seasonal flu vaccines for the 2016-2017 flu season. It was recommended that trivalent vaccines for use in the 2016-2017 influenza season (Northern Hemisphere winter) contain the following:
- an A/California/7/2009 (H1N1)pdm09-like virus;
- an A/Hong Kong/4801/2014 (H3N2)-like virus;
- a B/Brisbane/60/2008-like virus (B/Victoria lineage).
It was recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus (B/Yamagata lineage).
The vaccine viruses recommended for inclusion in the 2016-2017 Northern Hemisphere influenza vaccines are the same vaccine viruses that were chosen for inclusion in 2016 Southern Hemisphere seasonal flu vaccines.